Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.
PTC Therapeutics's Capital Expenditure for the
three
months ended in Mar. 2022 was $-81.45 Mil. Its Revenue for the
three
months ended in Mar. 2022 was $148.74 Mil.
Hence, PTC Therapeutics's Capex-to-Revenue for the
three
months ended in Mar. 2022 was 0.55.
PTC Therapeutics Capex-to-Revenue Historical Data
The historical data trend for PTC Therapeutics's Capex-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
PTC Therapeutics Annual Data
Trend
Dec12
Dec13
Dec14
Dec15
Dec16
Dec17
Dec18
Dec19
Dec20
Dec21
Capex-to-Revenue
0.41
0.06
0.15
0.15
0.16
PTC Therapeutics Quarterly Data
Jun17
Sep17
Dec17
Mar18
Jun18
Sep18
Dec18
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Mar22
Capex-to-Revenue
0.17
0.13
0.19
0.15
0.55
Competitive Comparison
For the Biotechnology subindustry, PTC Therapeutics's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PTC Therapeutics Capex-to-Revenue Distribution
For the Biotechnology industry and Healthcare sector, PTC Therapeutics's Capex-to-Revenue distribution charts can be found below:
* The bar in red indicates where PTC Therapeutics's Capex-to-Revenue falls into.
PTC Therapeutics Capex-to-Revenue Calculation
PTC Therapeutics's Capex-to-Revenue for the fiscal year that ended in Dec. 2021 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.
PTC Therapeutics Capex-to-Revenue Related Terms
Thank you for viewing the detailed overview of PTC Therapeutics's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
PTC Therapeutics Inc is a global biopharmaceutical company focused on the discovery, development, and commercialization of orally administered, small-molecule therapeutics. Its target area is RNA biology post-transcriptional control processes of the events occurring in a cell when a RNA messenger is copied from DNA during the transcription process. The discovered products address multiple therapeutic areas, including rare disorders, such as nonsense mutations in Duchenne muscular dystrophy and oncology.
My Portfolios
Create New Portfolio
Portfolio Contest
My Gurus
Personalize
Premium Gurus 
1.08(3.44%) Volume: 259,901 1:29PM EDT
Email Alerts
Stock PDF
RSS
Website
Filings
Download
Manual of Stocks™ Web APP
NAS:PTCT has been successfully added to your 
